MiMedx Group (NASDAQ:MDXG) Reaches New 12-Month Low – Here’s What Happened

MiMedx Group, Inc (NASDAQ:MDXG)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as $4.08 and last traded at $4.1050, with a volume of 296123 shares traded. The stock had previously closed at $4.13.

Wall Street Analyst Weigh In

MDXG has been the subject of a number of research reports. Lake Street Capital dropped their price objective on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday, January 20th. Citizens Jmp started coverage on MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating and a $10.00 target price on the stock. Wall Street Zen downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Citigroup assumed coverage on shares of MiMedx Group in a research note on Monday, February 23rd. They set a “market outperform” rating on the stock. Finally, UBS Group set a $10.00 price target on shares of MiMedx Group in a research report on Monday, February 23rd. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.60.

MiMedx Group Stock Down 0.7%

The firm has a market cap of $609.14 million, a PE ratio of 12.81 and a beta of 1.60. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $4.96 and a two-hundred day moving average price of $6.25.

MiMedx Group (NASDAQ:MDXG) last released its earnings results on Wednesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The firm had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. On average, equities research analysts expect that MiMedx Group, Inc will post 0.3 EPS for the current year.

Hedge Funds Weigh In On MiMedx Group

Institutional investors and hedge funds have recently made changes to their positions in the stock. First Light Asset Management LLC increased its stake in shares of MiMedx Group by 89.5% during the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after buying an additional 1,725,458 shares during the period. Divisadero Street Capital Management LP lifted its stake in MiMedx Group by 362.9% in the second quarter. Divisadero Street Capital Management LP now owns 223,220 shares of the company’s stock worth $1,364,000 after acquiring an additional 175,000 shares during the last quarter. Hussman Strategic Advisors Inc. purchased a new position in MiMedx Group in the third quarter worth approximately $1,759,000. Trigran Investments Inc. grew its holdings in MiMedx Group by 10.4% during the 2nd quarter. Trigran Investments Inc. now owns 8,390,458 shares of the company’s stock worth $51,266,000 after acquiring an additional 790,901 shares in the last quarter. Finally, SG Americas Securities LLC grew its holdings in MiMedx Group by 419.3% during the 3rd quarter. SG Americas Securities LLC now owns 161,960 shares of the company’s stock worth $1,130,000 after acquiring an additional 130,769 shares in the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.